Wolfgang Miesbach: Half of All Haemophilia Patients on Prophylaxis are Still Having Breakthrough Bleeds
Wolfgang Miesbach, shared post on LinkedIn about a recent article by Sheena Thakkar et al., published in Blood Coagulation and Fibrinolysis, adding:
“Half of all haemophilia patients on prophylaxis are still having breakthrough bleeds – and when they bleed, it’s the joint.
New real-world data from the Adelphi Haemophilia DSP (Thakkar et al., Blood Coagul Fibrinolysis 2026) – 739 men with haemophilia A, 131 with haemophilia B, six countries, physician-reported:
- Emicizumab was already the most-used treatment in HA (40%), EHL factor in HB (55%)
- Yet 48% (HA) and 54% (HB) had breakthrough bleeds since switching to their current prophylaxis
- Among those who bled, joint bleeds dominated in both: 53% and 57%
Haemophilia B was not the milder disease
Prophylaxis is not the same as protection. As long as the joint remains the target organ, ‘well controlled’ on paper can still mean progressive arthropathy in the clinic.
These data were collected in 2020/21 — before Efanesoctocog alfa, gene therapy, and the current generation of non-factor agents reached routine practice.”
Title: Describing the clinical outcomes and treatment landscape for male haemophilia A and B patients in a real-world setting across Europe and the United States
Authors: Sheena Thakkar, Lisa J. Wilcox, Valeria Merla, Anna Kane, Rabiyah Sahar, Chris Blazos, Sophie Lai, Ella Morton, Kieran Wynne-Cattanach, Nathan Ball.

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance